Skip to main content

Table 2 Top 5 genes from the subnetworks of each dataset based on their betweenness and degree centrality scores, depicting compound-specific signature genes in each cell line

From: A systems pharmacology approach based on oncogenic signalling pathways to determine the mechanisms of action of natural products in breast cancer from transcriptome data

ACT (MDA-MB-453)

CKI (MCF-7)

I3C (MCF-7)

I3C (MDA-MB-157)

I3C (MDA-MB-231)

I3C (MDA-MB-436)

I3C (T47D)

I3C (ZR751)

WA (MCF-7)

WA (MDA-MB-231)

APP

ELAVL1

TRIM25

HNRNPL

HNRNPL

HNRNPL

HNRNPL

HNRNPL

APP

TRIM25

TRIM25

HNRNPL

ELAVL1

ESR2

ELAVL1

TRIM25

TRIM25

TRIM25

TRIM25

ELAVL1

ELAVL1

APP

ESR2

TRIM25

ESR2

ESR2

ELAVL1

ELAVL1

ESR2

APP

ESR2

TRIM25

HNRNPL

CUL3

CUL3

ELAVL1

ESR2

APP

ELAVL1

RNF4

HNRNPL

RNF4

APP

BAG3

CDH1

APP

APP

RNF4

HNRNPL

NXF1

  1. The genes are labelled using their respective universal identifiers. ACT Actein, CKI Compound kushen injection, I3C Indole-3-carbinol, and WA Withaferin A.